Kronos Bio, Inc. - Common Stock (KRON)
Frequently Asked Questions About Kronos Bio, Inc. - Common Stock (KRON)
Does Kronos Bio have any collaborations with academic institutions?
Yes, Kronos Bio has established collaborations with various academic institutions and research organizations. These partnerships aim to leverage academic expertise in cancer biology and drug discovery to enhance the development of its therapeutic candidates.
Has Kronos Bio entered any partnerships?
Yes, Kronos Bio has formed strategic partnerships with other biotechnology and pharmaceutical companies to enhance its research and development capabilities. These collaborations aim to advance the development and commercialization of its therapeutic candidates.
How can I invest in Kronos Bio?
Investing in Kronos Bio can be done through any brokerage account that provides access to the Nasdaq stock exchange. Interested investors should conduct their own research and consider the risks associated with investing in biotechnology companies before making investment decisions.
How does Kronos Bio approach drug discovery?
Kronos Bio employs a target-driven approach to drug discovery, focusing on understanding the underlying cancer biology. The company utilizes advanced technologies and methodologies to identify and optimize small molecules that can disrupt cancer progression.
Is Kronos Bio publicly traded?
Yes, Kronos Bio is a publicly traded company. It completed its initial public offering (IPO) in 2020, allowing investors to purchase shares and participate in the company's growth.
What are the latest developments for Kronos Bio?
The latest developments for Kronos Bio include advancements in their clinical trial programs and ongoing research initiatives. The company regularly updates its stakeholders on progress at investor conferences and through press releases detailing new findings and strategic milestones.
What are the potential risks associated with Kronos Bio?
Potential risks associated with Kronos Bio include the inherent uncertainties of drug development, regulatory challenges, competition in the biotech industry, and financial instability. Investors should carefully consider these factors when evaluating the company's potential for success.
What are the primary research focuses of Kronos Bio?
Kronos Bio's primary research focuses include the development of small molecules that target transcription factors and epigenetic regulators involved in cancer. The company's approach is centered on understanding the biology of cancer to create innovative therapeutic candidates.
What does Kronos Bio, Inc. do?
Kronos Bio, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies for patients with cancer. The company's primary focus is on the treatment of hematological malignancies and solid tumors through the development of small-molecule therapeutics that target specific cancer-causing pathways.
What is Kronos Bio's commitment to patient care?
Kronos Bio is committed to improving patient care through the development of innovative cancer treatments. The company prioritizes patient safety and efficacy in its clinical trials, aiming to deliver therapies that truly address the needs of patients facing cancer.
What is Kronos Bio's lead product candidate?
Kronos Bio's lead product candidate is called KB-0742. It is an orally administered small molecule designed to inhibit specific proteins involved in the growth and proliferation of cancer cells, indicating its potential use in treating various types of cancer.
What is the clinical trial pipeline of Kronos Bio?
Kronos Bio has an active clinical trial pipeline that includes multiple phases of clinical studies for its product candidates. The trials are designed to evaluate the safety, efficacy, and tolerability of its therapies in patients with specific types of cancer.
What is the funding status of Kronos Bio?
Kronos Bio has successfully raised capital through its initial public offering and subsequent funding rounds. This funding supports its research and development initiatives, clinical trials, and operational expenses as the company advances its product pipeline.
What is the mission of Kronos Bio?
The mission of Kronos Bio is to transform the lives of patients with cancer by developing novel therapeutic solutions that specifically target cancer-driving mechanisms. The company is committed to advancing cancer research and improving treatment options.
What is the significance of being listed on Nasdaq?
Being listed on Nasdaq provides Kronos Bio with increased visibility and credibility in the financial markets. It allows the company to attract more institutional and retail investors while also providing access to capital for future growth and research efforts.
What is the ticker symbol for Kronos Bio, Inc.?
The ticker symbol for Kronos Bio, Inc. is KRON. The company is traded on the Nasdaq stock exchange, allowing public investors to purchase and trade its shares.
What types of cancer is Kronos Bio targeting?
Kronos Bio is focused on targeting various types of cancers, particularly hematological malignancies such as acute myeloid leukemia (AML) and solid tumors. The company's research and development aim to develop therapies that address unmet needs in these areas.
When was Kronos Bio, Inc. founded?
Kronos Bio, Inc. was founded in 2018. The company was established by a team of experienced scientists and industry professionals with the goal of advancing cancer treatment through the development of novel therapeutic agents.
Where is Kronos Bio, Inc. headquartered?
Kronos Bio, Inc. is headquartered in San Francisco, California. This location places the company at the heart of the biotech industry, providing access to extensive resources, talent, and collaborations.
Who are the key executives at Kronos Bio?
Key executives at Kronos Bio include experienced leaders from the pharmaceutical and biotechnology industries. Notable individuals include the CEO, who has extensive background in drug development, and the CFO, who brings significant financial experience to the organization.
What is the current price of Kronos Bio, Inc. - Common Stock?
The current price of Kronos Bio, Inc. - Common Stock is 0.7052
When was Kronos Bio, Inc. - Common Stock last traded?
The last trade of Kronos Bio, Inc. - Common Stock was at 4:00 pm EDT on May 2nd, 2025
What is the market capitalization of Kronos Bio, Inc. - Common Stock?
The market capitalization of Kronos Bio, Inc. - Common Stock is 40.03M
How many shares of Kronos Bio, Inc. - Common Stock are outstanding?
Kronos Bio, Inc. - Common Stock has 56.77M shares outstanding.